IMU

1.89%

5.2¢ imugene limited

"that's why they bought Azer Zel."Unfortuantely I think you're...

First 154 Last

Share
Profile

Follow
mrdingo

4,198 Posts.

1187

10/04/24

07:42

Post #: 73268034
Share

Originally posted by Mason14: ↑

Lol. If you focus on preclinical data while ignoring clinical data, then this will be our last conversation

Still on the HER-Vaxx train, huh?

Simple, important question for you to answer:

If HER-Vaxx was so good, then why have IMU not done a head-to-head with Herceptin in a phase 2 trial for gastric cancer patients?
Moreover, Enhertu is outperforming Herceptin, so why aren't they challenging that with a head to head?

The reason they have not is because HER-Vaxx is not good enough.

Why are you citing preclinical data when the clinical data is all right there for CF33? CHECKvacc and CF33-hNIS are where you should be looking. If it was so sensitive at low doses in cell models, why is that not translating to the clinic. Here is the dosing protocol for T-Vec (approved) and CF33 in patients. Looks like CF33 is not 100 to 1000 times more potent. You would want to hope your runway runs deeep!

onCARlytics heading down the same path. Without the addition of PBMC, onCARlytics and Blinatumomab achieve a stable disease in a mouse model. With the so far inadequate efficacy of CF33 in patients, your program is shaping up terribly.

The B cell platform is dead. CF33 forms a backbone for 2 of your other programs. Limited activity for CF33 while injecting the drug DIRECTLY INTO PATIENTS CANCERS is beginning to erode the foundation of IMU, that's why they bought Azer Zel. If you can't generate more than 1 CR in a sweep of patients and cancer types, IMU will be trading at cash in the near future.

Expand

"that's why they bought Azer Zel."

Unfortuantely I think you're correct here. They knew the B-Cell platform wasn't going to cut it so they bought CF33 and Oncarlytics, they knew that wasn't going to cut it so they bought Azer cell.

Azer cell is now at the forefront of every presentation. B Cell hardly gets mentioned.

IMU Price at posting: 10.5¢ Sentiment: Buy Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

Is oil undervalued?

BOE

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

DVP

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

VMT

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

NXG

Cost blow-out for Rook I uranium project sees share plummet for NexGen

GRX

GreenX picks up prospective copper project in Germany

WGX

Westgold sets its sights on top five producer status through merger with Karora

VMS

Venture to sniff out high-grade REE targets at Jupiter project, WA

MGU

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

There are more pages in this discussion • 1 more message in this thread...

First 154 Last

Add IMU (ASX) to my watchlist

(20min delay)
Last 5.2¢		Change -0.001(1.89%)		Mkt cap ! $382.1M

Open	High	Low	Value	Volume
5.4¢	5.4¢	5.1¢	$674.9K	12.90M

Buyers (Bids)

No.	Vol.	Price($)
1	45087	5.2¢

Sellers (Offers)

Price($)	Vol.	No.
5.3¢	519803	5

View Market Depth

No.	Vol.	Price($)
1	45087	0.052
11	671034	0.051
81	7658639	0.050
23	3483045	0.049
19	831259	0.048

Price($)	Vol.	No.
0.053	384611	4
0.054	2188679	7
0.055	670630	7
0.056	1929043	11
0.057	1626859	12

Last trade - 16.10pm 02/08/2024 (20 minute delay)

IMU (ASX) Chart

"that's why they bought Azer Zel."Unfortuantely I think you're...

Is oil undervalued?

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

Cost blow-out for Rook I uranium project sees share plummet for NexGen

GreenX picks up prospective copper project in Germany

Westgold sets its sights on top five producer status through merger with Karora

Venture to sniff out high-grade REE targets at Jupiter project, WA

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

"that's why they bought Azer Zel."Unfortuantely I think you're...

Top Stories

Is oil undervalued?

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

Cost blow-out for Rook I uranium project sees share plummet for NexGen

GreenX picks up prospective copper project in Germany

Westgold sets its sights on top five producer status through merger with Karora

Venture to sniff out high-grade REE targets at Jupiter project, WA

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News